Number of items: 4.
2022
Christopoulos, Petros ,
Kluck, Klaus,
Kirchner, Martina,
Lüders, Heike,
Roeper, Julia,
Falkenstern-Ge, Roger-Fei,
Szewczyk, Marlen,
Sticht, Florian,
Saalfeld, Felix C. ,
Wesseler, Claas ,
Hackanson, Björn,
Dintner, Sebastian,
Faehling, Martin,
Kuon, Jonas,
Janning, Melanie,
Kauffmann-Guerrero, Diego,
Kazdal, Daniel,
Kurz, Sylke,
Eichhorn, Florian,
Bozorgmehr, Farastuk,
Shah, Rajiv ,
Tufman, Amanda,
Wermke, Martin,
Loges, Sonja,
Brueckl, Wolfgang M.,
Schulz, Christian,
Misch, Daniel,
Frost, Nikolaj ,
Kollmeier, Jens ,
Reck, Martin,
Griesinger, Frank,
Grohé, Christian,
Hong, Jin-Liern,
Lin, Huamao M.,
Budczies, Jan ,
Stenzinger, Albrecht and
Thomas, Michael
(2022)
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
European Journal of Cancer 170, pp. 106-118.
Fulltext not available.
Roeper, Julia,
Frost, Nikolaj,
Wermke, Martin,
Saalfeld, Felix C.,
Heudobler, Daniel,
Pukrop, Tobias,
Janning, Melanie,
Kuon, Jonas,
Fischer, Rieke,
Nogova, Lucia,
Christopoulos, Petros and
Griesinger, Frank
(2022)
Thorakale Onkologie – metastasierte Stadien.
Der Onkologe 28 (S1), pp. 55-60.
Fulltext not available.
2021
Frost, Nikolaj,
Christopoulos, Petros,
Kauffmann-Guerrero, Diego,
Stratmann, Jan,
Riedel, Richard,
Schaefer, Monica,
Alt, Jürgen,
Gütz, Sylvia,
Christoph, Daniel C.,
Laack, Eckart,
Faehling, Martin,
Fischer, Richard,
Fenchel, Klaus,
Haen, Sebastian,
Heukamp, Lukas,
Schulz, Christian and
Griesinger, Frank
(2021)
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Therapeutic Advances in Medical Oncology 13, p. 175883592098055.
Fulltext not available.
2020
Faehling, Martin,
Schumann, Christian,
Christopoulos, Petros,
Hoffknecht, Petra,
Alt, Jürgen,
Horn, Marlitt,
Eisenmann, Stephan ,
Schlenska-Lange, Anke,
Schütt, Philipp,
Steger, Felix,
Brückl, Wolfgang M. and
Christoph, Daniel C.
(2020)
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
Lung Cancer 150, pp. 114-122.
Fulltext not available.
This list was generated on Thu Dec 5 16:32:17 2024 CET.